Application No.: Not Yet Assigned Docket No.: 1752-0171PUS1

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the present application:

1-19. (Canceled)

20. (New) A pharmaceutical composition that elevates a dendritic cell precursor level in the blood, said pharmaceutical composition comprising:

MIP-1 α or a functional derivative thereof as the active ingredient; and a pharmaceutically acceptable carrier.

- 21. (New) The pharmaceutical composition of claim 20, wherein MIP-1 α is chemically modified with an amphipathic polymer.
- 22. (New) The pharmaceutical composition of claim 21 or 22, wherein the functional derivative of MIP-1 α is BB-10010.
- 23. (New) The pharmaceutical composition of claim 21, wherein the amphipathic polymer is a partially alkyl-esterified styrene maleic acid copolymer or a polyethylene glycol derivative.

Application No.: Not Yet Assigned Docket No.: 1752-0171PUS1

24. (New) A method of elevating a dendritic cell precursor level in the blood in a patient in need thereof, said method comprising:

administering an effective amount of MIP-1 α or a functional derivative thereof to said patient.

- 25. (New) The method of claim 24, wherein the administered functional derivative of MIP-1 α is BB-10010.
- 26. (New) The method of claim 24, wherein the administered functional derivative of MIP-1 α is MIP-1 α or BB-10010 which is chemically modified with an amphipathic polymer.
- 27. (New) The method of 26, wherein the amphipathic polymer is a partially alkyl-esterified styrene-maleic acid copolymer or a polyethylene glycol derivative.
- 28. (New) A functional derivative of MIP-1α, wherein the amphipathic polymer is a partially alkyl-esterified styrene-maleic acid copolymer or a polyethylene glycol derivative.